PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ -- Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation for PLX-200...
from PR Newswire: https://ift.tt/3BkxQG0
No comments:
Post a Comment